See Note 1 to our Consolidated Financial Statements for further details. ProductsProducts that have received marketing approval are summarized in the table below. The trial is being coordinated by researchers at the University of Oxford. We are responsible for the manufacture and supply of fasinumab globally. Many of these laws differ from each other in significant ways and have different effects. For financial information related to our one segment, see Part II, Item 6. " For example, as noted above in Part I, Item 1. " The ultimate impact of this pandemic is highly uncertain and subject to change. As a result, we may never be successful in fully commercializing REGEN-COV. In DME and RVO, EYLEA also competes with intravitreal implants of corticosteroids. The market for Dupixent\'s current and potential future indications is also competitive. We need to conduct both preclinical animal testing and human clinical trials. Many of our clinical trials are conducted under the oversight of IDMCs. Such interpretation can change and evolve over time. ITEM 1B. UNRESOLVED STAFF COMMENTSNone.